{"id":"recaticimab-intensive","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"null","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL5095381","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Recaticimab prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and enhancing anti-tumor activity.","oneSentence":"Recaticimab is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:24.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07002476","phase":"PHASE3","title":"Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-06-19","conditions":"Stroke","enrollment":652},{"nctId":"NCT07290699","phase":"PHASE4","title":"Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-01-01","conditions":"STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":2442},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Recaticimab (intensive)","genericName":"Recaticimab (intensive)","companyName":"Shanghai East Hospital","companyId":"shanghai-east-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recaticimab is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}